28.07.2021 • News

LyondellBasell Takes Over PolyPacific Polymers

LyondellBasell has taken over 100% of PolyPacific Polymers (PPM), a compounder based at Port Klang, Malaysia. The Malaysian production facility, which has capacity to produce 25,000 t/y of reinforced and modified polyolefin compounds, will be rebranded as LyondellBasell. All employees will transfer.

Simultaneously, the Rotterdam-based, Houston, Texas, USA-managed polyolefins giant has agreed to sell its 50% share in Australian PP compounder PolyPacific, parent company of the polymer producer, to co-owner Mirlex. The Australian private equity investor will then wholly own this company. 

The compounding operation that once belonged to BASF was acquired by Mirlex and Basell, the latter a predecessor of LyondellBasell, in 2001. At the time, Basell was a joint venture between BASF and Shell based at Rotterdam. Basell merged with Lyondell at the end of 2007.  Before the merger, the company belonged to Access Industries, private equity vehicle of Len Blavatnik.

Author: Dede Williams, Freelance Journalist

LyondellBasell has taken over 100% of PolyPacific Polymers (PPM), a compounder...
LyondellBasell has taken over 100% of PolyPacific Polymers (PPM), a compounder based at Port Klang, Malaysia. The production facility, which can make 25,000 t/y of reinforced and modified polyolefin compounds, will be rebranded as LyondellBasell. All employees will transfer. (c) PolyPacific Polymers

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read